MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Telemedicine,Telehealth, Mobile Health, mHealth, Virtual, Digital Health, DTx (Digital Therapeutics)
*Driving Forces: Telemedicine,Telehealth, mHealth & Home Health (Sectors)
*Driving Forces: Primary Care, Chronic Disease, Wellness, Weight Loss, Obesity, Coordinated Care
*Pioneers: Cardiology & Cardiovascular
Medical & Clinical Specialities
Diseases, Illnesses, Injury & Injuries
Schizophrenia
Parents
Diseases, Illnesses, Injury & Injuries
Mental Health
Neurological Disease
Children
*Develops novel drugs for the treatment of diseases and disorders of the central nervous system - specifically, neuropsychiatric and neurological conditions such as schizophrenia, bipolar depression, and behavior disturbances associated with dementia
*Licensed for $500,000 from Bristol Meyers Sqibb (Insomnia), Novartis (Schizophrenia)
*Schizophrenia Drug in Trials
10 Jan 2011 Mind-NRD (Switzerland) a development-stage biopharmaceutical company focused on a neurotrophic factor for the treatment of Parkinson’s, Alzheimer’s and schizophrenia, closed a $2M Series A financing.
2017: Intra-Cellular pulls off $150M funding as it preps schizophrenia drug filing
2017: NIH-NIDA/NIMH-PAR-14-230: Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R21/R33))=$725,000:LOI Due Date(s)-Mar15, 2015,Jul17, 2015,Nov15, 2015,Mar15, 2016,Jul16, 2016,Nov15, 2016, Mar17 2017:Exp-Apr18, 2017
2017: NIH-NIDA/NIMH-PAR-14-231:Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia(R33)=$450,000:LOI Due Date(s)-Mar15, 2015,Jul17, 2015,Nov15, 2015,Mar15, 2016,Jul16, 2016,Nov15, 2016, Mar17 2017:Exp-Apr18, 2017
2019: Here's Why Intra-Cellular Therapies Rose as Much as 176.8% Today
A Susceptibility Gene for Schizophrenia and Bipolar Disorder-University of Pennsylvania
Clinical-stage biopharmaceutical company focused on CNS disorders with an initial focus on Alzheimer’s and schizophrenia
Developing molecules to modify brain chemistry to treat schizophrenia, Parkinson’s disease, autism, and other disorders.
Developing novel compounds for the treatment of schizophrenia and other central nervous system disorders.
Employs functional neuroimaging to explore the underlying causes of schizophrenia and to subsequently assess the impact of new t
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)*
Molecular Correlates of Schizophrenia-University of Pennsylvania
Promentis Pharmaceuticals, Inc. for Schizophrenia and CNS Treatment
Reelin Diagnostic Test for Neuropsychiatric Disorders, including Schizophrenia, Autism, Depression, and Bipolar Disorder-University of Minnesota
Schizophrenia Research Foundation (SCARF)
SchizophreniaConnection.com
Sunovion Pharmaceuticals has announced that the FDA approved its once-daily, oral tablet for treating schizophrenia.(2010)
The chemistry platform has generated several drug products currently in preclinical development for treating a wide variety of diseases including schizophrenia.
TURNS-Treatment Units for Research on Neurocognition and Schizophrenia
Utilizes multi-modal and multi-scale imaging data from mouse models of neurological disorders to better understand schizophrenia